A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase I, single-arm, open-label, dose-escalation study in patients with stage II or III ovarian cancer after surgery. The study will evaluate the safety, tolerability, immune response, and preliminary clinical activity of NeoOVIV, a personalized mRNA-lipid nanoparticle vaccine, when given with standard adjuvant chemotherapy and a PD-1 antibody.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18-75 lat
- •Potwierdzony rak jajnika stadium II lub III
- •Przebyta operacja usunięcia guza z pozostawieniem niewielkich resztek (maksymalnie 1 mm) lub żadnych resztek
- •Dostępna próbka tkanki guza z operacji do badań genetycznych
- •Badania genetyczne wykazały co najmniej 5 zmutowanych genów, które mogą być atakowane przez szczepionkę
- •Brak widocznych resztek guza w obrazach tomografii po operacji
- •Dobry stan ogólny - pacjentka zdolna do codziennych czynności
- •Prawidłowe funkcjonowanie narządów wewnętrznych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 9, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
West China Hospital
Chengdu, China
Trial contact
Nan Lin, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.